Efforts to end AIDS could also reduce TB burden with proper funding

In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS." He says that "to fully succeed in Africa, where TB and HIV/AIDS are often two sides of the same coin, we have to quickly identify people who have TB or who are vulnerable to it and get them the services they need," which also means developing an accurate quick test for the disease.

Bryden continues, "Fortunately, research is proceeding on such a test, and U.S.-backed programs such as the President's Emergency Plan for AIDS Relief and the Global Fund are saving countless lives affected by both AIDS and TB. But we face a historic choice. Do we stall or even cut these programs to achieve a relatively tiny budget savings, as proposed in the House of Representatives, or do we push boldly forward? The answer is clear: We must seize this moment" (11/16).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Research suggests no need for yellow fever vaccine booster after initial dose